Dilip Shanghvi height - How tall is Dilip Shanghvi?

According to Forbes, as of October 2019, Shanghvi is the 12th richest person in India with a net worth of US$6.9 billion.

In 2019, journalist Soma Das authored The Reluctant Billionaire, the first and only biography of Dilip Shanghvi. Published by Penguin Random House, the book was nominated for Tata Literature Award in the Best Business Book category in November 2019.

In January 2018, the Indian government appointed Shanghvi to the Reserve Bank of India's 21-member central board committee. He is chairman of the board of governors at IIT Bombay. He was made a trustee of the Rhodes scholarship programme at Oxford University in 2017.

Shanghvi started Sun Pharmaceutical Industries with capital of INR 10,000 in 1982 at Vapi, with one psychiatry drug. In 1997, Sun acquired Caraco Pharma, a loss-making American company, with the aim of expanding Sun's reach in the United States. Sun also acquired Israel's Taro Pharma in 2007. Shanghvi stepped down as chairman and CEO in 2012 and chose Israel Makov, formerly CEO of Teva Pharmaceuticals, as his successor; Shanghvi became managing director. In April 2014 Sun, Ranbaxy, and Daiichi Sankyo (the majority shareholder in Ranbaxy) agreed that Sun would acquire all outstanding shares of Ranbaxy for $3.2 billion in Sun stock and that Sun would take on $800M in Ranbaxy debt; the deal closed in March 2015 and made Sun the largest drug company in India and fifth largest in the world, and made Daiichi the second largest shareholder in Sun.

Dilip Shanghvi (born 1 October 1955) is an Indian billionaire businessman and one of the country's richest people. He founded Sun Pharmaceuticals. The Government of India awarded him the civilian honour of the Padma Shri in 2016. India Today magazine ranked him 8th in India's most powerful people of 2017 list.